
https://www.science.org/content/blog-post/what-passes-positive-data
# What Passes For Positive Data
**5 Jan 2017**

## 1. SUMMARY

This article critiques Halozyme's Phase II trial results for PEGPH20, an enzyme designed to break down hyaluronan around pancreatic tumors to improve chemotherapy penetration. While the company and media portrayed the data as positive, the author reveals that the improved survival benefit vanished when looking at longer-term curves—by later timepoints, the standard-of-care group actually had more survivors. The trial narrowly met its primary endpoint (progression-free survival) but failed to show meaningful overall survival benefit, according to the analysis. This post illustrates how companies can selectively present data to create positive headlines while masking less impressive underlying results.

## 2. HISTORY

**PEGPH20's Clinical Trajectory:**
- **Phase II (2016):** Showed marginal progression-free survival benefit but no overall survival benefit in pancreatic cancer
- **Phase III (HALO-109-301, 2019):** Trial was halted early due to futility analysis showing PEGPH20 added to nab-paclitaxel/gemcitabine **failed to improve overall survival** compared to chemotherapy alone
- **Development discontinued:** Following the Phase III failure, Halozyme terminated the PEGPH20 pancreatic cancer program

**What This Meant:**
- No FDA approval was ever granted for PEGPH20 in pancreatic cancer
- The drug never reached clinical practice for the studied indication
- The company's earlier optimistic portrayals of Phase II data proved overhyped
- This became a cautionary example of progression-free survival benefits not translating to overall survival gains

**Halozyme's Pivot:**
- The company shifted focus to its ENHANZE drug delivery platform (using recombinant human hyaluronidase)
- ENHANZE found commercial success as a **drug delivery technology** rather than a standalone therapeutic
- Approved partnerships with multiple pharma companies to improve subcutaneous delivery of their biologics

## 3. PREDICTIONS

- **Article's implied prediction:** That PEGPH20 would fail to demonstrate meaningful clinical benefit in later trials
	- **Outcome:** ✅ **Correct** - Phase III trial showed no survival benefit and was halted for futility
- **Halozyme's press-release prediction:** That positive Phase II progression-free survival data supported advancing to Phase III
	- **Outcome:** ❌ **Incorrect** - despite advancing to Phase III, the drug ultimately failed to show benefit
- **Stock market's implied prediction:** Early stock bounce suggested investors believed in the therapeutic promise
	- **Outcome:** ❌ **Incorrect** - the drug development failure validated the article's skepticism over the original data

## 4. INTEREST

Rating: **7/10**

This article serves as an important cautionary piece about clinical data interpretation and industry hype versus clinical reality, with its skepticism validated by PEGPH20's subsequent Phase III failure.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20170105-what-passes-positive-data.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_